Format for disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Name of the Target Company (TC)	Medicamen Organics Limited		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	Acquirer: Bal Kishan Gupta		
Whether the acquirer belongs to Promoter / Promoter group	Yes		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	National Stock Exchange of India Limited ("**NSE-EMERGE**")		
Details of the acquisition / disposal as follows	Number	% w.r.t. total share/voting capital wherever applicable (*)	% w.r.t. total diluted share/voting capital of the TC (**)
Before the acquisition under consideration, holding of:			
a) Shares carrying voting rights	65,68,560	53.99	53.99
b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	-	-	-
c) Voting rights (VR) otherwise than by shares	-	-	-
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	-	-	-
e) Total (a+b+c+d)	65,68,560	53.99	53.99
Details of acquisition ~~/ sale~~			
a) Shares carrying voting rights acquired / sold	7,14,285	4.80	4.45
b) VRs acquired /sold otherwise than by shares	-	-	-
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired/sold	1,85,715	-	1.16
d) Shares encumbered / invoked / released by the acquirer	-	-	-
e) Total (a+b+c+/-d)	9,00,000	4.80	5.60

After the acquisition ~~/ sale~~, holding of: a) Shares carrying voting rights acquired b) Shares encumbered with the acquirer c) VRs otherwise than by shares d) Warrants / convertible securities / any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition e) Total (a+b+c+d)	72,82,845 - - 1,85,715 74,68,560	48.94 - 48.94	45.33 1.16 46.49
Mode of acquisition ~~/ sale~~ (e.g. open market / off-market / public issue / rights issue / preferential allotment / inter-se transfer etc).	Preferential allotment		
Date of ~~acquisition / sale of shares / VR or~~ date of receipt of intimation of allotment of shares, whichever is applicable	June 09, 2026, is the date of allotment of fully paid-up equity shares and warrants, convertible into Equity shares.		
Equity share capital / total voting capital of the TC before the said acquisition ~~/ sale~~	Prior to acquisition, the total equity paid-up share capital of the Company was INR 12,16,59,100/- (Indian Rupees twelve Crores Sixteen Lakhs Fifty-Nine Thousand One Hundred Only), comprising 1,21,65,910 equity shares at a face value of INR 10/- (Indian Rupees Ten Only) each.		
Equity share capital/ total voting capital of the TC after the said acquisition ~~/ sale~~	Post allotment of fully paid-up equity shares, the paid-up equity share capital is INR 14,88,01,950/- (Indian Rupees Fourteen Crores Eighty-Eight Lakhs One Thousand Nine Hundred Fifty Only), comprising 1,48,80,195 (One Crore Forty-Eight Lakhs Eighty Thousand One Hundred Ninety-Five) at a face value of INR 10/- (Indian Rupees Ten Only) each.		
Total diluted share/voting capital of the TC after the said acquisition	Post allotment of fully paid-up equity shares and warrants (on fully-diluted basis), the paid-up Equity share capital will be INR 16,06,59,100/- (Indian Rupees Sixteen Crores Six Lakhs Fifty-Nine Thousand One Hundred Only), comprising 1,60,65,910 (One Crore Sixty Lakhs Sixty-Five Thousand Nine Hundred Ten) at a face value of INR 10/- (Indian Rupees Ten Only) each.		

(*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement.

(**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Signature of the acquirer

Place: New Delhi
Date: June 10, 2026

******